Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey V Karakashev

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cancer Management and Research|August 29, 2015
Progress toward overcoming hypoxia-induced resistance to solid tumor therapySergey V Karakashev, Mauricio J Reginato
Oncotarget|January 19, 2015
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2Sergey V Karakashev, Mauricio J Reginato
The Journal of Biological Chemistry|April 16, 2013
The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistanceKelly A Whelan, Luciana P Schwab, Sergey V Karakashev, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cancer Management and Research|August 29, 2015
Progress toward overcoming hypoxia-induced resistance to solid tumor therapySergey V Karakashev, Mauricio J Reginato
Oncotarget|January 19, 2015
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2Sergey V Karakashev, Mauricio J Reginato
The Journal of Biological Chemistry|April 16, 2013
The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistanceKelly A Whelan, Luciana P Schwab, Sergey V Karakashev, et al.
Pageof 1